Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Agilent (A), Xencor (XNCR) and Pennant Group (PNTG)

Tipranks - Tipranks - Fri Feb 27, 9:24AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agilent (A – Research Report), Xencor (XNCR – Research Report) and Pennant Group (PNTG – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Agilent (A)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Agilent today and set a price target of $170.00. The company’s shares closed last Thursday at $117.56, close to its 52-week low of $116.36.

According to TipRanks.com, Arias is a 1-star analyst with an average return of -0.6% and a 44.7% success rate. Arias covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Tempus AI, Inc. Class A, and Guardant Health. ;'>

Agilent has an analyst consensus of Strong Buy, with a price target consensus of $166.83, which is a 36.9% upside from current levels. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $138.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Xencor (XNCR)

Cantor Fitzgerald analyst Steven Seedhouse reiterated a Buy rating on Xencor yesterday and set a price target of $43.00. The company’s shares closed last Thursday at $13.72.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 10.5% and a 43.5% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, NewAmsterdam Pharma Company, and Apellis Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xencor with a $29.00 average price target, which is a 133.3% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.

Pennant Group (PNTG)

Truist Financial analyst David S Macdonald maintained a Buy rating on Pennant Group today. The company’s shares closed last Thursday at $29.96.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 11.5% and a 59.3% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

Pennant Group has an analyst consensus of Strong Buy, with a price target consensus of $38.50, which is a 21.4% upside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $37.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).